Navigation Links
PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting
Date:3/16/2009

BOSTON, March 16 /PRNewswire/ -- PAREXEL experts will address the benefits of rigorous early phase clinical development at the 110th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), to be held at the Gaylord National Resort in National Harbor, Maryland from March 18 - 21, 2009. The focus of PAREXEL's presence at the ASCPT meeting will be to help biopharmaceutical companies understand best practice approaches for identifying and selecting the most promising new compounds earlier.

During the meeting, Klaus Franke, M.D., Clinical Research Physician, Early Phase, PAREXEL will present the poster "A Study to Validate a Capsaicin Model of Experimental Pain in Healthy Human Volunteers," co-authored with PAREXEL colleagues Matthias Grossmann, M.D., Ph.D., Vice President, Early Phase Consulting Services; Edward Neuhoff, Neurophysiologist; and Dawie Wessels, Senior Director and Early Phase Unit Head. Dr. Franke will address the use of pain modeling in early development and advantages of combining traditional pharmacodynamic methods with relevant neuroscience biomarkers to achieve the goal of alleviating pain and related symptoms. Dr. Franke will discuss how this approach to enhance exploration of safety and efficacy and pharmacokinetic analysis can be applied to a broad range of psychiatry, neuropsychopharmacology, neuroimaging, and neurophysiology clinical studies to provide greater information about Central Nervous System (CNS) treatments. The presentation will be given during Poster Session II, starting at 8:00 a.m. on Friday, March 20.

PAREXEL Early Phase experts will be available at Booth 111 in the exhibit hall to discuss how the Company's fully integrated First in Man through Proof of Concept services can help biopharmaceutical companies generate better and faster go/no go decisions about their compounds and return solid, reproducible outcomes to succeed in later-phase trials. PA
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009
2. PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting
3. PAREXEL Appoints Josephine Hoppe to Chief Information Officer
4. PAREXEL International to Present at the 27th Annual JP Morgan Healthcare Conference
5. PAREXEL Receives Best CRO Award from Scrip
6. PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies
7. PAREXEL Expands Pioneering Asian Ethnobridging Expertise
8. PAREXEL Expert to Address Key Aspects of Conducting Clinical Trials in China at 7th Annual Partnerships in Clinical Trials Congress
9. PAREXEL International to Present at Oppenheimer 19th Annual Healthcare Conference
10. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
11. PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement Award From Good Clinical Practice Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- BioScrip, Inc. (NASDAQ: BIOS ) today announced ... Global Healthcare Conference to be held June 3-6, 2013 ... Richard Smith , President and Chief Executive ... Financial Officer, will present on Monday, June 3, 2013 ... About BioScrip BioScrip, Inc. provides comprehensive infusion and ...
(Date:5/23/2013)... , May 23, 2013  Rahal Letterman Lanigan Racing ... cord blood stem cell banking and therapeutics, announced today ... No. 16 Acorn Stairlifts Indy car driven by ... remainder of the IZOD IndyCar 2013 season.   ... work to support awareness of umbilical cord blood banking ...
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. today ... pain has reached an important milestone, as Virobay has ... - a selective cathepsin S inhibitor.   ... double-blind, randomized, placebo-controlled study designed to evaluate the safety, ... in healthy adults. "The initiation of this ...
(Date:5/23/2013)... May 23, 2013 The New Jersey ... industries, Black Data Processing Associates (BDPA), is hosting its ... 8, 2013. This all-day event will encourage students and ... the ins and outs from many of the industries’ ... at the New Jersey Institute of Technology, the event ...
Breaking Biology Technology:StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2
... ... 2009 and is now serving 7 of the Top 10 pharmaceutical and 3 of the ... ... 2009 -- OpenQ, a leading provider of technology and information solutions for the life sciences ...
... , , WAYNE, Pa., July 17 ... ENCO ), a full service multinational clinical research organization ... clinical trials and patient registries to many of the ... completed the previously announced sale of the Company,s U.S. ...
... , HOPKINTON, Mass., July 16 ... a conference call discussing the company,s second quarter 2009 financial results ... President and Chief Executive Officer and Peter McAree, Chief Financial Officer, ... and the company,s outlook for the future. , ...
Cached Biology Technology:OpenQ Posts a 200% Revenue Growth in the First Half of 2009 2Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes 2Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes 3Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes 4Caliper Life Sciences' Second Quarter 2009 Financial Results Conference Call Notice 2
(Date:5/23/2013)... By discovering the new mechanism by which estrogen suppresses ... revealed a potential new approach toward treating certain liver ... and colleagues believe they are changing long-held views in ... issue of the journal Science Signaling . , ... years has been that only receptors located in the ...
(Date:5/23/2013)... Some prostate cancer patients unnecessarily undergo surgery or ... differences between slow-growing and aggressive forms of the ... Johns Hopkins Medical Institutes are developing technology that ... opt for relatively mild treatments or take drastic ... Anant Madabhushi, an associate professor of biomedical engineering ...
(Date:5/23/2013)... world are billions of animal and plant specimens from ... all stacked, stored and preserved in jars and collection ... critical to understanding how the Earth,s biodiversity is changing ... if only the information were easily accessible. , A ... of a team from the University of Colorado Boulder, ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4
... been shed on proteorhodopsin, the light-sensitive protein found in ... of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) and ... when the ability to respire oxygen is impaired, bacterium ... carry out vital life processes. , ...
... onset of type 1 diabetes in mice prone to ... on the surface of immune T-cells. According to the ... January issue of the journal Diabetes, have significant implications ... More than 700,000 Americans have type 1 diabetes, an ...
... soon be able to cultivate new tomato varieties without ... This is the conclusion of the STW-sponsored thesis by ... to earn his doctorate on 3 April 2007. Finkers ... resistant to grey mould. The leading company De Ruiter ...
Cached Biology News:Shedding new light on proteorhodopsin 2Shedding new light on proteorhodopsin 3Antibody therapy prevents type 1 diabetes in mice 2Research on grey mould offers possible breakthrough in tomato cultivation 2
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
TXNL2 Antibody...
Goat polyclonal to Glucose Dehydrogenase ( Abpromise for all tested applications). Antigen: Glucose Dehydrogenase (Bacillus species)...
Goat polyclonal to HNF4 ( Abpromise for all tested applications). Antigen: Synthetic peptide: RLSKTLVDMDMADY (Human) N terminal. Entrez GeneID: 3172 Swiss Protein ID: P41235...
Biology Products: